Sunmax Biotechnology Co., Ltd. (TPEX:4728)

Market Cap	21.32B -4.4%
Revenue (ttm)	2.04B +4.7%
Net Income	724.03M -0.3%
EPS	13.27 -0.4%
Shares Out	54.46M
PE Ratio	29.50
Forward PE	n/a
Dividend	12.10 (3.14%)
Ex-Dividend Date	Mar 31, 2026

Volume	33
Open	391.50
Previous Close	391.50
Day's Range	391.50 - 391.50
52-Week Range	350.00 - 431.50
Beta	-0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About Sunmax Biotechnology

Sunmax Biotechnology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of biomedical-grade collagen and related products in Taiwan, Mainland China, and internationally. It offers collagen dermal filler sets, such as Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO injectable collagen gel with lidocaine. The company was founded in 2001 and is based in Tainan City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4728

Financial Performance

In 2025, Sunmax Biotechnology's revenue was 2.03 billion, an increase of 11.45% compared to the previous year's 1.82 billion. Earnings were 725.75 million, an increase of 6.82%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 19, 2026

Data Sources Report a data error